 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 04/27/2001 | | | | Nymox Expands E. Coli Product Development
topic: R&D: E coli and Other Antibacterial Treatments
April 27, 2001: Nymox Pharmaceutical Corporation announced today that it has entered into a formal collaboration agreement with the Food Research and Development Centre of the Department of Agriculture and Agri-Food Canada in St. Hyacinthe, Quebec and with the University of Montreal to study animal and meat treatments for E. coli O157:H7, the deadly bacteria implicated in contamination of meat and other food and drink products and of drinking water supplies. |
| 04/11/2001 | | | | New Clinical Trial Publication Supports Nymox's AlzheimAlert™ Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (April 11, 2001) – Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today a new specialist peer-review publication documenting the results of a successful large new clinical trial for its AlzheimAlert™ urinary test. The trial was a double-blind study involving Alzheimer’s disease patients and normal controls, with overall 140 participants from five institutions. |
| 04/05/2001 | | | | Nymox Adds Significant Value to Global Patent Holdings
topic: Financial
MAYWOOD, NJ (April 5, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the company’s R&D activities have been increasingly productive in the past year in generating patentable products and company patent applications. In the past eighteen months, the company and its affiliates have drafted, filed and prosecuted over fourteen U.S. patent applications, as well as a substantially larger number of foreign patent applications. |
| 03/29/2001 | | | | Large New Community Study Proves Usefulness of Nymox's AlzheimAlert™ Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (March 29, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that the results of a significant large new study have strongly confirmed the accuracy and usefulness of the company’s AlzheimAlert™ urinary test to aid in the diagnosis of Alzheimer’s disease. The clinical study involved urinary test samples from a random independent community-based cohort of 122 individuals from across the U.S. The AlzheimAlert™ test accurately distinguished Alzheimer’s disease patients from normals in over 90% of the cases. |
| 03/27/2001 | | | | Importance of Spherons in Alzheimer's Disease Highlighted by New Study
topic: R&D: Spherons and Alzheimer's Disease
March 27, 2001: Nymox Pharmaceutical Corporation announced today that a recently completed study has found strong new evidence confirming the link between spherons and senile plaques – the characteristic lesion found abundantly in the brains of patients with Alzheimer’s disease and believed by many researchers to play a pivotal role in the fatal illness. |
| 03/23/2001 | | | | Nymox's NicAlert™ Measures Best Biomarker for Tobacco Use and Exposure
topic: Tobacco Exposure Tests
MAYWOOD, NJ (March 23, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to note that the first National Report on Human Exposure to Environmental Chemicals, released by the Centers for Disease Control and Prevention on March 21, 2001, confirms that the biomarker detected by NicAlert™ is the best for testing for tobacco exposure, including second-hand smoke exposure. The Report further underlines the public health consequences of smoking or using smokeless tobacco products. |
| 03/19/2001 | | | | Nymox Announces Appointment of Scientific Consultants, Dr. Thomas Hudson and Dr. Joe Dylewski
topic: Appointments
MAYWOOD, NJ (March 19, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the appointment of Dr. Thomas J. Hudson, M.D., and Dr. Joe Dylewski, M.D. as scientific consultants. |
| 03/13/2001 | | | | Nymox Developing New Drug Candidates for the Treatment of Alzheimer's Disease
topic: R&D: Alzheimer's Disease Treatments
MAYWOOD, NJ (March 13, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it is increasing its development efforts in the areas of diagnosing and treating Alzheimer’s disease, the leading cause of dementia among the elderly. |
| 03/08/2001 | | | | Experts Recommend Nymox's NicAlert™ Test
topic: Tobacco Exposure Tests
MAYWOOD, NJ (March 8, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that new research studies have led to strong independent endorsements of Nymox’s new NicAlert™ test. The new urinary and saliva tests are being used in institutions throughout the United States in studies of smoking behavior, tobacco exposure, monitoring and risk. |
| 03/01/2001 | | | | New Clinical Trial Data Supports Nymox's AlzheimAlert™ Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (March 1, 2001) – Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today the results of a successful large new clinical trial for its AlzheimAlert™ urinary test. The trial was a multi-site double-blind study involving Alzheimer’s disease patients and normal controls. Overall there were 168 participants in the trial from five institutions. |
|